TechNavio recognizes the following companies as the key players in the Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market: Pfizer Inc., Cubist Pharmaceuticals Inc., ViroPharma Inc., Forest Laboratories Inc., and Theravance Inc.
Commenting on the report, an analyst from TechNavio’s Healthcare team said: ”The most common trend witnessed in the Global MRSA Drugs market is various governmental and non-governmental awareness programs that are informing people about the advanced treatments and educating people about the spread of infections. Moreover, vendors are supporting such comprehensive care programs through awareness campaigns for educating people about the spread and the treatment of infectious diseases.”
According to the report, the increase in the prevalence of MRSA infections has increased the usage of drugs used against MRSA infection across the globe.
Further, the report states that the rapid development of resistance to existing therapies is a major factor hampering the growth of the Global MRSA Drugs market.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Basilea Pharmaceutica Ltd., Durata Therapeutics Inc., Novartis AG, Trius Therapeutics Inc., AstraZeneca plc, and GlaxoSmithKline plc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/content/global-methicillin-resistant-staphyloco…
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our Engineering market research, please visit https://www.technavio.com/healthcare
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report “ Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market 2012-2016
